Core Insights - The company reported a 100% year-over-year revenue growth for 2025, achieving a total revenue of $96.1 million in Q4, which is a 113% increase from $45.1 million in the same quarter of the previous year [1][3][7] - The company raised its 2026 revenue guidance to a range of $430 million to $445 million, indicating a growth of 41% to 46% from 2025 [4][16] Financial Performance - For the full year 2025, the company delivered 610,000 tests, a 51% increase from 2024, with an average selling price (ASP) rising 35% to $495 [2] - Operating income for 2025 was $16.0 million, compared to an operating loss of $47.1 million in 2024, resulting in a 5% operating margin [2] - Adjusted EBITDA was reported at $38.8 million, reflecting a 13% margin [2][3] - Gross profit for Q4 was $68.6 million, with a gross margin expansion to 71.4% from 57% [9] Product and Clinical Developments - The company expanded its UNITY prenatal offerings and launched Northstar add-ons for oncology, including the first platelet fetal-antigen NIPT [5][10] - The company secured Medicare coverage for Northstar Select and signed 44 payer contracts, reaching approximately 250 million contracted lives [6][14] Market Access and Strategic Initiatives - The company signed an in-network agreement with UnitedHealthcare, which is expected to enhance reimbursement predictability [15] - Management highlighted potential upside drivers not included in the revenue guidance, such as health system adoption and future EMR integrations [18] Sales Force Expansion - The company plans to increase its prenatal sales representatives from approximately 150 to 185 and oncology sales representatives from about 45 to 65 by the end of 2026 [19]